In-vitro assessment of drug resistance to albendazole and rafoxanide in Fasciola hepatica in sheep

Document Type : Research Paper

Authors

Department of Pathobiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.

10.22059/ijas.2024.361150.653952

Abstract

Fasciolosis is an important parasitic disease that limits the productivity of ruminants. During the last two decades, anthelmintic drugs have been increasingly applied in Iran. The aim of the present study was to evaluate drug resistance of Fasciola hepatica to albendazole and rafoxanide in sheep under laboratory conditions in Marivan municipality, West of Iran. For this purpose, a total number of 290 sheep livers were collected. They were cut into small pieces and adult F. hepatica were removed from naturally infected livers of sheep. Then were count and crushed. About 1,000 eggs of F. hepatica in 0.9% Ringer’s solution were provided and incubated at 28˚C for 16 days. On the 14th day, albendazole (0.1 μg/ml) and rafoxanide (0.1 μg/ml) along with control group were incubated at 28˚C for 48 h. The percentage of hatched eggs and lethal dose of 50% larvae (LD50) were figure out. Overall, 50 out of 290 examined livers (17.24%) were positive for F. hepatica infection. The highest infection rate of F. hepatica was found in the winter (2.17%). There was significant difference between percentage of the hatched eggs and both treated with albendazole and rafoxanide and control groups. The average of the hatched eggs of F. hepatica was lower in rafoxanide treated group (19.6±17.6) than albendazole treated group (32.8±14.9) and control group (35.4±12.1). LD50 did not demonstrate resistance to albendazole (32.75%) and rafoxanide (19.5%) in treated groups. It was concluded that there was no resistance to albendazole and rafoxanide in sheep.

Keywords

Main Subjects



Articles in Press, Accepted Manuscript
Available Online from 03 December 2024
  • Receive Date: 08 July 2023
  • Revise Date: 23 June 2024
  • Accept Date: 31 August 2024